TABLE 2.
Clinical features in different risk subgroups.
| Characteristics | TCGA-BRCA | METABRIC-BRCA | GSE3494-BRCA | ||||||
|---|---|---|---|---|---|---|---|---|---|
| High risk | Low risk | p Value | High risk | Low risk | p Value | High risk | Low risk | p Value | |
| number(%) | 960 | 1900 | 234 | ||||||
| 480 (50) | 480 (50) | 1252 (65.9) | 648 (34.1) | 70 (30) | 164 (70) | ||||
| Age (%) | 0.003 | <0.001 | 0.309 | ||||||
| <60y | 283 (29.5) | 237 (24.7) | 598 (31.5) | 241 (12.7) | 31 (13.2) | 61 (26.1) | |||
| ≥60y | 197 (20.5) | 243 (25.3) | 654 (34.4) | 407 (21.4) | 39 (16.7) | 103 (44) | |||
| Race(%) | <0.001 | ||||||||
| White | 289 (30.1) | 377 (39.3) | — | — | — | — | — | ||
| Black | 117 (12.2) | 51 (5.3) | — | — | — | ||||
| Asian and other | 36 (3.7) | 16 (1.7) | — | — | — | — | |||
| NA | 38 (4) | 36 (3.8) | — | — | — | — | |||
| Tumor grade(%) | — | <0.001 | <0.001 | ||||||
| G1 | — | — | 54 (2.8) | 110 (5.8) | 7 (3) | 55 (23.5) | |||
| G2 | — | — | 370 (19.5) | 370 (19.5) | 28 (12) | 92 (39.3) | |||
| G3 | — | — | 788 (41.5) | 137 (7.2) | 35 (15) | 15 (6.4) | |||
| NA | — | — | 40 (2.1) | 31 (1.6) | — | 2 (0.9) | |||
| Histological type(%) | <0.001 | <0.001 | |||||||
| IDC | 430 (44.8) | 274 (28.5) | 1028 (54.1) | 422 (22.2) | — | — | |||
| ILC | 28 (2.9) | 163 (16.9) | 64 (3.4) | 78 (4.1) | — | — | |||
| Other | 22 (2.2) | 43 (4.5) | 161 (8.4) | 148 (7.8) | — | — | |||
| Menopause status(%) | 0.723 | <0.001 | |||||||
| Pre | 106 | 103 | 301 (15.8) | 110 (5.8) | — | — | |||
| Post | 302 | 314 | 951 (50.1) | 538 (28.3) | — | — | |||
| Peri | 18 | 19 | — | — | — | — | |||
| NA | 54 | 44 | — | — | — | — | |||
| ER status(%) | <0.001 | <0.001 | <0.001 | ||||||
| Positive | 274 (28.5) | 442 (46) | 814 (42.8) | 643 (33.8) | 51 (22.2) | 149 (93.1) | |||
| Negative | 188 (19.6) | 15 (1.6) | 438 (23.1) | 5 (0.3) | 19 (8.3) | 11 (4.8) | |||
| NA | 18 (1.9) | 23 (2.4) | — | — | |||||
| PR status(%) | <0.001 | — | — | <0.001 | <0.001 | ||||
| Positive | 224 (23.3) | 400 (41.7) | 496 (26.1) | 511 (26.9) | 40 (17.1) | 138 (59) | |||
| Negative | 239 (24.9) | 54 (5.6) | 756 (39.8) | 137 (7.2) | 30 (12.8) | 26 (11.1) | |||
| NA | 17 (1.78) | 26 (2.7) | — | — | — | — | |||
| HER2 status(%) | <0.001 | — | — | <0.001 | |||||
| Positive | 114 (11.9) | 55 (5.7) | 227 (11.9) | 9 (0.5) | — | — | |||
| Negative | 306 (31.9) | 366 (38.1) | 1027 (54.1) | 640 (33.7) | — | — | |||
| NA | 63 (6.6) | 59 (6.1) | — | — | |||||
| Molecular subtype | <0.001 | <0.001 | |||||||
| HR+/Her2- | 182 (19) | 353 (60) | 732 (38.5) | 646 (33.4) | — | — | |||
| HR+/Her2+ | 77 (16) | 55 (11.5) | 96 (7.7) | 8 (1.2) | — | — | |||
| HR-/Her2+ | 33 (3.4) | 0 | 131 (6.9) | 1 (0.1) | — | — | |||
| TNBC | 123 (12.8) | 12 (1.3) | 295 (15.5) | 4 (1.3) | — | — | |||
| NA | 65 (6.8) | 60 (12.5) | — | — | — | — | |||
| TNM stage(%) | 0.045 | <0.001 | |||||||
| 0 | 3 (0.2) | 1 (0.1) | — | — | |||||
| I | 67 (7) | 99 (10.3) | 263 (13.8) | 210 (11.1) | — | — | |||
| II | 279 (29.1) | 266 (27.7) | 560 (29.5) | 240 (12.6) | — | — | |||
| III | 113 (11.8) | 98 (10.2) | 98 (5.2) | 17 (0.9) | — | — | |||
| IV | 12 (1.3) | 6 (0.6) | 7 (0.4) | 2 (0.1) | — | — | |||
| NA | 9 (0.9) | 11 (1.1) | 321 (16.9) | 178 (9.4) | — | — | |||
| Follow up state(%) | |||||||||
| Alive | 428 (44.6) | 455 (47.4) | 776 (40,8) | 503 (26.5) | 48 (20.5) | 132 (56.4) | |||
| Dead | 52 (5.4) | 25 (2.6) | 476 (25.1) | 145 (7.6) | 22 (9.4) | 32 (13.7) | |||
| DSS years (median) | 2.4 | 2.5 | 8.7 | 10.6 | 9.9 | 10.4 | |||